Abstract
A new galenical formulation containing 1 mg lormeta-zepam (LMZ) for sublingual administration (“sleeping wafer”, see Figure 1) has been developed. In an open-cross over design the plasma lormetazepam levels were monitored radioimmunologically in 16 volunteers. Subjects received the sublingual formulation and an oral tablet (NoctamidR-1) in a randomized sequence at weekly intervals. After sublingual administration the mean plasma lormetazepam levels were significantly higher between 7.5 and 25 minutes than after administration of the tablet. The earlier rise in plasma LMZ levels is also reflected in partial areas under the plasma level curve up to 45 minutes. LMZ was completely absorbed from both formulations as shown in total AUCs.It is anticipated that sublingual administration of the new formulation will lead to a 40 - 50 % reduction of sleep latency. Possibilities for therapeutic application of the new formulation are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
